Anaptysbio (ANAB) Gains from Sales and Divestitures (2025 - 2026)
Anaptysbio posted quarterly Gains from Sales and Divestitures of $34300.0 for Q1 2026, down 90.36% on a QoQ basis from $355627.0 in Q4 2025.
Anaptysbio (ANAB) has 2 years of Gains from Sales and Divestitures data on file, last reported at $34300.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures changed N/A year-over-year to $34300.0; the trailing twelve-month figure through Mar 2026 stood at $34300.0 (changed N/A YoY), and the FY2025 full-year result was $355627.0, changed N/A from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $34300.0, down from $355627.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $355627.0 in Q4 2025 and bottomed at $34300.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34,300.00 |
| Mar 31, 2026 | 34,300.00 |
| Dec 31, 2025 | 355,627.00 |
| Dec 31, 2025 | 355,627.00 |